



**Lindare Medical Ltd**

HTA licensing number 22577

Licensed under the Human Tissue (Quality and Safety for Human Application) Regulations 2007 (as amended)

**Licensable activities carried out by the establishment**

**Licensed activities – Human Tissue (Quality and Safety for Human Application) Regulations 2007 (as amended)**

‘E’ = Establishment is licensed to carry out this activity and is currently carrying it out.

Site	Procurement	Processing	Testing	Storage	Distribution	Import	Export
Lindare Medical Ltd				E	E	E	

**Tissue types authorised for licensed activities – Human Tissue (Quality and Safety for Human Application) Regulations 2007 (as amended)**

Authorised = Establishment is authorised to carry out this activity and is currently carrying it out.

Tissue Category; Tissue Type	Procurement	Processing	Testing	Storage	Distribution	Import	Export
Musculoskeletal, Bone; Bone Strut				Authorised	Authorised	Authorised	
Musculoskeletal, Bone; Cancellous				Authorised	Authorised	Authorised	

<b>Bone Particles</b>							
<b>Musculoskeletal, Bone; DBM* putty</b>				Authorised	Authorised	Authorised	

\*DBM = demineralised bone matrix

### **Summary of Virtual Regulatory Assessment (VRA) findings**

The HTA found the Designated Individual (DI) and the Licence Holder (LH) to be suitable in accordance with the requirements of the legislation.

Although the HTA found that Lindare Medical Ltd (the establishment) had met the majority of the HTA's standards that were assessed during the VRA, one major shortfall was found against standards for Governance and Quality and five minor shortfalls were found against standards for Governance and Quality, and Premises, Facilities and Equipment.

The HTA has assessed the establishment as suitable to be licensed for the activities specified, subject to corrective and preventative actions being implemented to meet the shortfalls identified during the VRA.

## Compliance with HTA standards

### *Major Shortfall*

Standard	VRA findings	Level of shortfall
<b>GQ2 There is a documented system of quality management and audit.</b>		
c) An audit is conducted in an independent manner at least every two years to verify compliance with protocols and HTA standards, and any findings and corrective actions are documented.	The last independent audit was undertaken before the HTA inspection in 2016. There is no audit scheduled or agreement in place with an independent auditor. As this was a minor shortfall after the 2018 inspection, it has now been upgraded to a major shortfall.	<b>Major</b>

### *Minor Shortfalls*

Standard	VRA findings	Level of shortfall
<b>GQ2 There is a documented system of quality management and audit.</b>		
b) There is an internal audit system for all licensable activities.	Three separate audits were chosen from the audit schedule in advance of the VRA and these were discussed ('Temperature controls', 'Traceability of goods', 'Quarantine procedures'). Audit findings and action plans were informally distributed throughout different document folders but there was no formal system for recording audit findings, discussion and actions implemented.	<b>Minor</b>

**GQ3 Staff are appropriately qualified and trained in techniques relevant to their work and are continuously updating their skills.**

f) There is a documented training programme that ensures that staff have adequate knowledge of the scientific and ethical principles relevant to their work, and the regulatory context.	There is no documented regulatory training programme for staff working under the licence.	<b>Minor</b>
--	---	--------------

**GQ6 A coding and records system facilitates traceability of bodies, body parts, tissues and cells, ensuring a robust audit trail.**

d) The requirements of the Single European Code are adhered to as set out in Directions 002/2018.	For direct imports, the Single European Code (SEC) is applied by the establishment. For products received from the Netherlands, it is already applied. In both cases, the SEC is applied to the outside of the box containing the product but not to the primary product packaging or in any accompanying documentation.	<b>Minor</b>
---	--	--------------

**GQ7 There are systems to ensure that all adverse events are investigated promptly.**

a) There are procedures for the identification, reporting, investigation and recording of adverse events and reactions, including documentation of any corrective or preventative actions.	During the VRA an incident relating to temperatures exceeding the maximum range was discussed. Although this incident had been informally discussed by staff at the establishment, there was no formal procedure for the management of non-reportable incidents.	<b>Minor</b>
--	--	--------------

**PFE5 Equipment is appropriate for use, maintained, quality assured, validated and where appropriate monitored.**

b) Critical equipment is maintained and serviced in accordance with the manufacturer's instructions.	The temperature measuring devices have not been calibrated or tested regularly to ensure that their alarms are working at the appropriate temperatures.	<b>Minor</b>
--	---	--------------

The HTA requires the DI to submit a completed corrective and preventative action (CAPA) plan setting out how the shortfalls will be addressed, within 14 days of receipt of the final report (refer to Appendix 3 for recommended timeframes within which to complete actions). The HTA will then inform the establishment of the evidence required to demonstrate that the actions agreed in the plan have been completed.

### DI and CLH suitability

The HTA found the Designated Individual (DI) and the Corporate Licence Holder (CLH) to be suitable in accordance with the requirements of the legislation.

### Advice

The HTA advises the DI to consider the following to further improve practice:

Number	Standard	Advice
1.	N/A	The current CLH contact (CLHc) is also the DI. This is not the HTA's preferred arrangement, which is that the CLHc should be more senior than the DI to enable them to replace the DI, if necessary. The DI is advised to consider exploring if an alternative arrangement is possible.
2.	N/A	The DI is advised to consider appointing a Person Designated (PD) to assist him in the role. This would be especially important on those occasions when the DI is absent. The HTA must be notified of such an appointment.
3.	GQ2(a)	The establishment is accredited under ISO 9001: 2015 and ISO 14001: 2015 and the Quality Manual is written against these standards. The DI is advised to consider incorporating the HTA standards into this document.
4.	GQ2(c)	The HTA has published guidance on independent audits, which can be found on the ' <a href="#">Independent audits</a> ' page of the HTA website. The DI is advised to consider reading this guidance when preparing its audit strategy.

5.	GQ3(f)	<p>The DI is advised to consider incorporating the following into the establishment's regulatory training programme:</p> <ul style="list-style-type: none"> <li>- relevant parts (especially 'import' and 'coding' sections) of the <a href="#">'Guide to Quality and Safety Assurance of Human Tissues and Cells for Patient Treatment'</a>; and</li> <li>- the <a href="#">Human Tissue (Quality and Safety for Human Application) Regulations 2007 (as amended) Test Questions</a> created by the HTA.</li> </ul>
6.	GQ4(b)	<p>During the audit the following discrepancies were noted:</p> <ul style="list-style-type: none"> <li>• not all fields of the 'Donor batch and release checklist form' (H006) were completed in two cases that were reviewed;</li> <li>• Form H006 quoted the French supplier, even when it applied to direct imports from the USA; and</li> <li>• there is duplication of the sample management procedure (H004: 'Human tissue standard operating procedure' and H005: 'Procedures for the handling of acellular human tissue products from purchase to sale').</li> </ul> <p>The DI is advised to consider modifying the records audit schedule to incorporate checks of a kind that would identify such omissions and duplications.</p>
7.	GQ7(a)	<p>The HTA should be notified by the licensed establishment within 24 hours of the discovery or determination of an SAEAR. The DI is advised to consider updating and standardising its documentation relating to SAEAR reporting to reflect this (H003: 'Terms and conditions of supply'; H005: 'Procedures for the handling of acellular human tissue products from purchase to sale'; H011: 'Guidelines for reporting serious adverse events or reactions').</p>
8.	PFE3(c)	<p>The DI is advised to consider regularly challenging the audible temperature alarm and temperature alarm callout system to ensure that it is functioning correctly, and to document these checks.</p>

## **Background**

Lindare Medical Ltd is an importing tissue establishment (ITE) and imports acellular bone products from a third country supplier (3CS) in the United States of America (USA). It also receives acellular bone products from a French company whose storage facility is based in the Netherlands. The establishment supplies orthopaedic departments within UK public and private sector hospitals.

The establishment has been licensed by the HTA since September 2009. This was the establishment's first VRA undertaken by the HTA. Prior to this, four site visit inspections of the establishment had been conducted, the most recent of these being in May 2018.

There have been changes to the nominated DI since the last inspection. The Managing Director, who was the DI until February 2018, has been re-appointed as an interim measure.

## **Description of VRA activities undertaken**

The HTA's regulatory requirements are set out in Appendix 2. The following areas were covered during the VRA:

### *Review of governance documentation*

The following documents were reviewed: policies and procedural documents relating to licensed activities, contracts for servicing of equipment and records of servicing, temperature monitoring records, contingency arrangements and agreements.

The review of information related to the quality management system included: meeting minutes, audits, staff training records, reported incidents and adverse events, and risk assessments.

### *Audit of records and other documentation*

The traceability audit included a review of six acellular products (two DBM putties, one cancellous cube product, two cancellous bone particles and one granules product). Two of these were direct imports, the remaining four had been received via the Netherlands. The products were selected from the electronic tissues register previously provided by the establishment. The Single European Code (SEC) and other labelling information, as well as

details of order, receipt, product location, release to end-user (one product), customer return and disposal (one product) were reviewed. There were discrepancies noted with two of the samples (see *Advice*, item 4). The training records of one representative member of staff who handled the products were also checked. No discrepancies were noted.

For the direct imports, the following information was received from the 3CS and reviewed: donor selection, procurement and consent forms, mandatory serological test results, and sample sterility analysis before terminal sterilisation. There were no discrepancies noted.

Three of the establishment's internal audits were reviewed. The scope of each audit was discussed, along with audit findings and actions implemented.

One reported incident was reviewed. The root cause of the incident was discussed, along with corrective and preventative actions implemented.

**Report sent to DI for factual accuracy: 29 December 2020**

**Report returned from DI: 06 January 2021**

**Final Report issued: 19 January 2021**

## Appendix 1: HTA standards

The HTA standards applicable to this establishment are shown below; those not assessed during the VRA are shown in grey text. Individual standards which are not applicable to this establishment have been excluded.

### Human Tissue (Quality and Safety for Human Application) Regulations 2007 Standards

#### Consent

Standard
C1 Consent is obtained in accordance with the requirements of the HT Act 2004, the Human Tissue (Quality and Safety for Human Application) Regulations 2007 and as set out in the HTA's Codes of Practice.
b) If there is a third party procuring tissues and / or cells on behalf of the establishment the third party agreement ensures that consent is obtained in accordance with the requirements of the HT Act 2004, the Q&S Regulations and the HTA's Codes of Practice.
c) The establishment or the third party's procedure on obtaining donor consent includes how potential donors are identified and who is able to take consent.
C2 Information about the consent process is provided and in a variety of formats.
b) If third parties act as procurers of tissues and / or cells, the third party agreement details what information will be provided to donors. As a minimum, the information specified by Directions 002/2018 is included.

#### Governance and Quality

Standard
GQ1 All aspects of the establishment's work are supported by ratified documented policies and procedures as part of the overall governance process.
a) There is an organisational chart clearly defining the lines of accountability and reporting relationships.

b) There are procedures for all licensable activities that ensure integrity of tissue and / or cells and minimise the risk of contamination.
c) There are regular governance meetings, for example health and safety, risk management and clinical governance committees, which are recorded by agendas and minutes.
d) There is a document control system to ensure that changes to documents are reviewed, approved, dated and documented by an authorised person and only current documents are in use.
f) There are procedures for tissue and / or cell procurement, which ensure the dignity of deceased donors.
g) There are procedures to ensure that an authorised person verifies that tissues and / or cells received by the establishment meet required specifications.
h) There are procedures for the management and quarantine of non-conforming consignments or those with incomplete test results, to ensure no risk of cross contamination.
i) There are procedures to ensure tissues and / or cells are not released from quarantine until verification has been completed and recorded.
k) There is a procedure for handling returned products.
l) There are procedures to ensure that in the event of termination of activities for whatever reason, stored tissues and / or cells are transferred to another licensed establishment or establishments.
m) The criteria for allocating tissues and / or cells to patients and health care institutions are documented and made available to these parties on request.
n) The establishment ensures imports from non-EEA states meet the standards of quality and safety set out in Directions 002/2018.
o) There is a complaints system in place.
p) There are written agreements with third parties whenever an activity takes place that has the potential to influence the quality and safety of human tissues and / or cells.

q) There is a record of agreements established with third parties.
r) Third party agreements specify the responsibilities of the third party and meet the requirements set out in Directions 002/2018.
s) Third party agreements specify that the third party will inform the establishment in the event of a serious adverse reaction or event.
t) There are procedures for the re-provision of service in an emergency.
GQ2 There is a documented system of quality management and audit.
a) There is a quality management system which ensures continuous and systematic improvement.
b) There is an internal audit system for all licensable activities.
c) An audit is conducted in an independent manner at least every two years to verify compliance with protocols and HTA standards, and any findings and corrective actions are documented.
d) Processes affecting the quality and safety of tissues and / or cells are validated and undergo regular evaluation to ensure they continue to achieve the intended results.
GQ3 Staff are appropriately qualified and trained in techniques relevant to their work and are continuously updating their skills.
a) There are clearly documented job descriptions for all staff.
b) There are orientation and induction programmes for new staff.
c) There are continuous professional development (CPD) plans for staff and attendance at training is recorded.
d) There is annual documented mandatory training (e.g. health and safety and fire).
e) Personnel are trained in all tasks relevant to their work and their competence is recorded.

f) There is a documented training programme that ensures that staff have adequate knowledge of the scientific and ethical principles relevant to their work, and the regulatory context.
g) There is a documented training programme that ensures that staff understand the organisational structure and the quality systems used within the establishment.
h) There is a system of staff appraisal.
i) Where appropriate, staff are registered with a professional or statutory body.
j) There are training and reference manuals available.
k) The establishment is sufficiently staffed to carry out its activities.
<b>GQ4 There is a systematic and planned approach to the management of records.</b>
a) There are procedures for the creation, identification, maintenance, access, amendment, retention and destruction of records.
b) There is a system for the regular audit of records and their content to check for completeness, legibility and accuracy and to resolve any discrepancies found.
c) Written records are legible and indelible. Records kept in other formats such as computerised records are stored on a validated system.
d) There is a system for back-up / recovery in the event of loss of computerised records.
e) The establishment keeps a register of the types and quantities of tissues and / or cells that are procured, tested, preserved, processed, stored and distributed or otherwise disposed of, and on the origin and destination of tissues and cells intended for human application.
f) There are procedures to ensure that donor documentation, as specified by Directions 002/2018, is collected and maintained.
g) There is a system to ensure records are secure and that donor confidentiality is maintained in accordance with Directions 002/2018.

h) Raw data which are critical to the safety and quality of tissues and cells are kept for 10 years after the use, expiry date or disposal of tissues and / or cells.
i) The minimum data to ensure traceability from donor to recipient as required by Directions 002/2018 are kept for 30 years after the use, expiry or disposal of tissues and / or cells.
k) There are documented agreements with end users to ensure they record and store the data required by Directions 002/2018.
l) The establishment records the acceptance or rejection of tissue and / or cells that it receives and in the case of rejection why this rejection occurred.
m) In the event of termination of activities of the establishment a contingency plan to ensure records of traceability are maintained for 10 or 30 years as required.
GQ5 There are documented procedures for donor selection and exclusion, including donor criteria.
a) Donors are selected either by the establishment or the third party acting on its behalf in accordance with the criteria required by Directions 002/2018.
b) The testing of donors by the establishment or a third party on behalf of the establishment is carried out in accordance with the requirements of Directions 002/2018.
d) There is a system in place either at the establishment or at a third party acting on its behalf to record results of donor selection and associated tests.
GQ6 A coding and records system facilitates traceability of tissues and / or cells, ensuring a robust audit trail.
a) There is a donor identification system which assigns a unique code to each donation and to each of the products associated with it.
b) An audit trail is maintained, which includes details of when the tissues and / or cells were acquired and from where, the uses to which the tissues and / or cells were put, when the tissues and / or cells were transferred elsewhere and to whom.

c) The establishment has procedures to ensure that tissues and / or cells imported, procured, processed, stored, distributed and exported are traceable from donor to recipient and vice versa.
d) The requirements of the Single European Code are adhered to as set out in Directions 002/2018.
GQ7 There are systems to ensure that all adverse events, reactions and/or incidents are investigated promptly.
a) There are procedures for the identification, reporting, investigation and recording of adverse events and reactions, including documentation of any corrective or preventative actions.
b) There is a system to receive and distribute national and local information (e.g. HTA regulatory alerts) and notify the HTA and other establishments as necessary of serious adverse events or reactions.
c) The responsibilities of personnel investigating adverse events and reactions are clearly defined.
d) There are procedures to identify and decide the fate of tissues and / or cells affected by an adverse event, reaction or deviation from the required quality and safety standards.
e) In the event of a recall, there are personnel authorised within the establishment to assess the need for a recall and if appropriate initiate and coordinate a recall.
f) There is an effective, documented recall procedure which includes a description of responsibilities and actions to be taken in the event of a recall including notification of the HTA and pre-defined times in which actions must be taken.
g) Establishments distributing tissue and / or cells provide information to end users on how to report a serious adverse event or reaction and have agreements with them specifying that they will report these events or reactions.
h) Establishments distributing tissues and / or cells have systems to receive notifications of serious adverse events and reactions from end users and notify the HTA.

GQ8 Risk assessments of the establishment's practices and processes are completed regularly and are recorded and monitored appropriately.

a) There are documented risk assessments for all practices and processes.

b) Risk assessments are reviewed regularly, as a minimum annually or when any changes are made that may affect the quality and safety of tissues and cells.

c) Staff can access risk assessments and are made aware of local hazards at training.

d) A documented risk assessment is carried out to decide the fate of any tissue and / or cells stored prior to the introduction of a new donor selection criteria or a new processing step, which enhances the quality and safety of tissue and / or cells.

#### **Premises, Facilities and Equipment**

##### **Standard**

PFE1 The premises are fit for purpose.

a) A risk assessment has been carried out of the premises to ensure that they are fit for purpose.

b) There are procedures to review and maintain the safety of staff, visitors and patients.

c) The premises have sufficient space for procedures to be carried out safely and efficiently.

e) There are procedures to ensure that the premises are secure and confidentiality is maintained.

f) There is access to a nominated, registered medical practitioner and / or a scientific advisor to provide advice and oversee the establishment's medical and scientific activities.

PFE2 Environmental controls are in place to avoid potential contamination.

a) Tissues and / or cells stored in quarantine are stored separately from tissue and / or cells that have been released from quarantine.

c) There are procedures for cleaning and decontamination.
PFE3 There are appropriate facilities for the storage of tissues and / or cells, consumables and records.
a) Tissues, cells, consumables and records are stored in secure environments and precautions are taken to minimise risk of damage, theft or contamination.
b) There are systems to deal with emergencies on a 24-hour basis.
c) Tissues and / or cells are stored in controlled, monitored and recorded conditions that maintain tissue and / or cell integrity.
d) There is a documented, specified maximum storage period for tissues and / or cells.
PFE4 Systems are in place to protect the quality and integrity of tissues and / or cells during transport and delivery to its destination.
a) There is a system to ensure tissue and / or cells are not distributed until they meet the standards laid down by Directions 002/2018.
b) There are procedures for the transport of tissues and / or cells which reflect identified risks associated with transport.
c) There is a system to ensure that traceability of tissues and / or cells is maintained during transport.
d) Records are kept of transportation and delivery.
e) Tissues and / or cells are packaged and transported in a manner and under conditions that minimise the risk of contamination and ensure their safety and quality.
g) Critical transport conditions required to maintain the properties of tissue and / or cells are defined and documented.
h) Packaging and containers used for transportation are validated to ensure they are fit for purpose.

i) Primary packaging containing tissues and / or cells is labelled with the information required by Directions.
j) Shipping packaging containing tissues and / or cells is labelled with the information required by Directions.
PFE5 Equipment is appropriate for use, maintained, quality assured, validated and where appropriate monitored.
a) Critical equipment and technical devices are identified, validated, regularly inspected and records are maintained.
b) Critical equipment is maintained and serviced in accordance with the manufacturer's instructions.
c) Equipment affecting critical processes and storage parameters is identified and monitored to detect malfunctions and defects and procedures are in place to take any corrective actions.
d) New and repaired equipment is validated before use and this is documented.
e) There are documented agreements with maintenance companies.
f) Cleaning, disinfection and sanitation of critical equipment is performed regularly and this is recorded.
h) Users have access to instructions for equipment and receive training in the use of equipment and maintenance where appropriate.
i) Staff are aware of how to report an equipment problem.
j) For each critical process, the materials, equipment and personnel are identified and documented.
k) There are contingency plans for equipment failure.

## Disposal

Standard
D1 There is a clear and sensitive policy for disposing of tissues and / or cells.
a) The disposal policy complies with HTA's Codes of Practice.
b) The disposal procedure complies with Health and Safety recommendations.
c) There is a documented procedure on disposal which ensures that there is no cross contamination.
D2 The reasons for disposal and the methods used are carefully documented.
a) There is a procedure for tracking the disposal of tissue and / or cells that details the method and reason for disposal.
b) Disposal arrangements reflect (where applicable) the consent given for disposal.

## **Appendix 2: The HTA's regulatory requirements**

The HTA must assure itself that the DI, Licence Holder, premises and practices are suitable.

The statutory duties of the DI are set down in Section 18 of the Human Tissue Act 2004. They are to secure that:

- the other persons to whom the licence applies are suitable persons to participate in the carrying-on of the licensed activity;
- suitable practices are used in the course of carrying on that activity; and
- the conditions of the licence are complied with.

The HTA developed its licensing standards with input from its stakeholders. They are designed to ensure the safe and ethical use of human tissue and the dignified and respectful treatment of the deceased. The HTA inspects the establishments it licences against four groups of standards:

- consent
- governance and quality systems
- premises facilities and equipment
- disposal.

This is an exception-based report: only those standards that have been assessed as not met are included. Where the HTA determines that a standard is not met, the level of the shortfall is classified as 'Critical', 'Major' or 'Minor' (see Appendix 2: Classification of the level of shortfall). Where HTA standards are fully met, but the HTA has identified an area of practice that could be further improved, advice is given to the DI.

Reports of HTA inspections and Virtual Regulatory Assessments carried out from 1 November 2010 are published on the HTA's website.

### **Appendix 3: Classification of the level of shortfall (HA)**

Where the HTA determines that a licensing standard is not met, the improvements required will be stated and the level of the shortfall will be classified as 'Critical', 'Major' or 'Minor'. Where the HTA is not presented with evidence that an establishment meets the requirements of an expected standard, it works on the premise that a lack of evidence indicates a shortfall.

The action an establishment will be required to make following the identification of a shortfall is based on the HTA's assessment of risk of harm and/or a breach of the Human Tissue Act 2004, Human Tissue (Quality and Safety for Human Application) Regulations 2007, or associated Directions.

#### **1. Critical shortfall:**

A shortfall which poses a significant direct risk of causing harm to a recipient patient or to a living donor,

*or*

A number of 'major' shortfalls, none of which is critical on its own, but viewed cumulatively represent a systemic failure and therefore are considered 'critical'.

A critical shortfall may result in one or more of the following:

- A notice of proposal being issued to revoke the licence
- Some or all of the licensable activity at the establishment ceasing with immediate effect until a corrective action plan is developed, agreed by the HTA and implemented.
- A notice of suspension of licensable activities
- Additional conditions being proposed
- Directions being issued requiring specific action to be taken straightaway

#### **2. Major shortfall:**

A non-critical shortfall.

A shortfall in the carrying out of licensable activities which poses an indirect risk to the safety of a donor or a recipient

*or*

A shortfall in the establishment's quality and safety procedures which poses an indirect risk to the safety of a donor or a recipient;

*or*

A shortfall which indicates a major deviation from the Human Tissue (Quality and Safety for Human Application) Regulations 2007 or the HTA Directions;

*or*

A shortfall which indicates a failure to carry out satisfactory procedures for the release of tissues and cells or a failure on the part of the designated individual to fulfil his or her legal duties;

*or*

A combination of several 'minor' shortfalls, none of which is major on its own, but which, viewed cumulatively, could constitute a major shortfall by adversely affecting the quality and safety of the tissues and cells.

In response to a major shortfall, an establishment is expected to implement corrective and preventative actions within 1-2 months of the issue of the final VRA report. Major shortfalls pose a higher level of risk and therefore a shorter deadline is given, compared to minor shortfalls, to ensure the level of risk is reduced in an appropriate timeframe.

### **3. Minor shortfall:**

A shortfall which cannot be classified as either critical or major and, which can be addressed by further development by the establishment.

This category of shortfall requires the development of a corrective action plan, the results of which will usually be assessed by the HTA either by desk-based review or at the time of the next on-site inspection or VRA.

In response to a minor shortfall, an establishment is expected to implement corrective and preventative actions within 3-4 months of the

issue of the final VRA.

### **Follow up actions**

A template corrective and preventative action plan will be sent as a separate Word document with the final VRA. Establishments must complete this template and return it to the HTA within 14 days of the issue of the final report.

Based on the level of the shortfall, the HTA will consider the most suitable type of follow-up of the completion of the corrective and preventative action plan. This may include a combination of

- a follow-up site-visit inspection
- a request for information that shows completion of actions
- monitoring of the action plan completion
- follow up at next routine site-visit inspection.

After an assessment of your proposed action plan you will be notified of the follow-up approach the HTA will take.